With reference to the "Rules Governing Issuers of Securities Listed on the
Copenhagen Stock Exchange A/S" we hereby announce that Pharmexa has scheduled
the following dates in 2008 for the annual general meeting and for the release
of financial reports:
March 3, 2008 Release of annual report for 2007
April 28, 2008 Annual General Meeting
May 9, 2008 Release of interim financial report, 1st quarter 2008
August 21, 2008 Release of interim financial report, 2nd quarter 2008
November 7, 2008 Release of interim financial report, 3rd quarter 2008
Hørsholm, December 3, 2007
Jakob Schmidt
Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication,
telephone +45 4516 2525 or +45 4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, GENimmune, IDM Pharma and
Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs
approximately 105 people and is listed on the Copenhagen Stock Exchange under
the trading symbol PHARMX.
